Genetic variation underlying common hereditary hyperbilirubinaemia (Gilbert's syndrome) and respiratory health in the 1946 British birth cohort by Horsfall, LJ et al.
Research ArticleGenetic variation underlying common hereditary
hyperbilirubinaemia (Gilbert’s syndrome) and
respiratory health in the 1946 British birth cohort
Laura J. Horsfall1,3,⇑, Rebecca Hardy2, Andrew Wong2, Diana Kuh2, Dallas M. Swallow3
1Research Department of Primary Care and Population Health, Institute of Epidemiology & Health, University College London, UK; 2MRC
University Unit for Lifelong Health and Ageing at University College London, UK; 3Research Department of Genetic, Environment and Evolution,
University College London, UKBackground & Aims: Bilirubin has potent antioxidant properties
in vitro and raised serum levels have been associated with lower
rates of respiratory disease. The enzyme uridine diphosphate glu-
curonosyltransferase polypeptide 1A1 (UGT1A1) is solely respon-
sible for clearing bilirubin from the blood and homozygosity for
seven thymine-adenine (TA) repeats in the TATA box regulatory
element of the UGT1A1 gene underlies a mild hereditary unconju-
gated hyperbilirubinaemia (Gilbert’s syndrome). Our aim was to
investigate whether this genetic variation is associated with dif-
ferences in respiratory health.
Methods: The relationship between the promoter genotype
underlying Gilbert’s syndrome (UGT1A1 rs8175347 [TA]7/7) and
respiratory outcomes assessed at ages 43, 53, and 60–64 were
examined in 2190 members of the 1946 British birth cohort.
Results: The (TA)7/7 genotype, present in 9% of the cohort, was
associated with higher forced expiratory volume (FEV1) and
forced vital capacity (FVC). The relationship was strongest for
heavy smokers (P20 cigarettes per day) at age 53 with mean
FEV1 409 ml higher (191 to 627; p <0.001) and mean FVC
530 ml higher (95% CI 262–798; p <0.001) for UGT1A1 (TA)7/7
Gilbert’s syndrome participants than for all others, indicating a
protection from the pulmonary consequences of heavy smoking.
The odds of respiratory disease (chronic obstructive pulmonary
disease, self-reported asthma, or prescription of respiratory
drugs) were half in those with Gilbert’s syndrome genotype (odds
ratio 0.49 [95% CI 0.39–0.74]; p <0.001) compared to those with-
out this genotype.Journal of Hepatology 20
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Respiratory systems are exposed to reactive oxygen species (ROS)
from sources such as cigarette smoke, air pollution and indoor
cooking/heating ﬁres [1]. Interindividual differences in the blood
levels of ROS scavengers may partially explain differences in the
susceptibility to smoking-related respiratory disease [2].
Bilirubin is the yellow-coloured end product of the haem
catabolism pathway in mammals. The enzyme haem oxygenase
generates an insoluble form of bilirubin from haem that is
transported to the liver and is converted to a water-soluble (con-
jugated) form by the enzyme uridine diphosphate-glucuronosyl-
transferase (UGT1A1). Potent cytoprotective properties including
antioxidant have been reported for both the unconjugated and
conjugated forms of bilirubin [3,4]. Various lines of experimental
evidence mainly involving animal models suggest a role for
serum bilirubin in protecting respiratory tissues against environ-
mental stressors [5]. For example, bilirubin infusions can protect
against bleomycin-induced pulmonary ﬁbrosis in rats [6]. Cohort
studies have reported lower rates of respiratory diseases and
increased respiratory function in people with comparatively
higher serum bilirubin levels after accounting for important con-
founders including smoking status [7–9]. However reverse causa-
tion where the disease process alters bilirubin levels or residual
confounding by unmeasured confounders could potentially
explain these relationships.
Genome wide association studies have repeatedly identiﬁed
UGT1A1 as the major genetic locus underlying bilirubin levels in
European, East Asian and African populations [10–12]. The
UGT1A1 rs8175347 thymine-adenine (TA) polymorphism of the
TATA box regulatory motif is well characterized in European pop-
ulations since homozygosity for a low expresser variant ([TA]7 or
[TA]8 repeats vs. [TA]5 or [TA]6) underlies a common form of14 vol. 61 j 1344–1351
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familial unconjugated hyperbilirubinaemia (Gilbert’s syndrome;
OMIM 143500) [13]. Finding an association between this com-
mon promoter variation, causing unconjugated hyperbilirubina-
emia, and improved respiratory health could support a
protective role for bilirubin previously suggested by animal
experiments and observational studies in humans [14]. Unlike
disease association studies using serum bilirubin levels, the
potential for association being due to reverse causation is low
because the UGT1A1 genotype is determined at birth and unaf-
fected by the disease process. The random allocation of parental
alleles at conception should in principle balance observed and
unobserved confounders across genotype groups reducing the
potential for residual confounding. This type of genetic associa-
tion study is sometimes termed ‘‘Mendelian randomization’’
although causal inference using this design relies on some impor-
tant assumptions [14].
In the present study, we used data from the Medical Research
Council (MRC) National Survey of Health and Development
(NSHD), commonly known as the 1946 British birth cohort study,
to investigate the relationship between a genetic variation in
UGT1A1, underlying Gilbert’s syndrome, and adult respiratory
health as well as interactions with age and smoking status.Patients and methods
Study population
The NSHD is the longest continuously running birth cohort in the world with
details on sampling strategy, data collections, attrition and representativeness
reported elsewhere [15–17]. In brief, the NSHD comprises a socially stratiﬁed
sample of 5362 births out of a total of 16,695 registered in England, Wales and
Scotland in one week in the year 1946 [16,18]. The cohort includes all singleton
births to wives of non-manual and agricultural workers and 1 in 4 singleton
births to wives of manual workers. The cohort participants have been followed
since birth with the most recent contact phase between the ages of 60 and 64
[15]. At age 53, 3035 of the original cohort were invited to provide a DNA sample.
Contact was not attempted for individuals who had already died (n = 476), were
living abroad (n = 583), had previously refused to take part (n = 648), or were
untraced since the last contact at 43 years (n = 266). The sociodemographic fea-
tures of the participants at ages 43 and 53 were broadly representative of the
British post-war generation compared with the 1991 England Census data for
the national population but with some over-representation of the widowed, or
married women and men with lower educational attainment [17]. The sociode-
mographic features of participants at ages 60–64 appear to be similar to the
2001 England Census reference population, although there were lower levels of
home ownership and limiting illness [15]. The cohort participants were selected
prior to major immigration ﬂows and so white British ethnicity is over-repre-
sented relative to the UK adult population. Additional details on the cohort,
including numbers lost to follow-up at various contact phases with reasons, are
included in the Supplementary Patients and methods section. DNA was obtained
and successfully extracted from blood and/or buccal samples for 2939 out of the
3035 participants at age 53 [18] The study protocol was approved by the Medical
Research and Ethics Committee (approval reference MREC 98/2/121 and MREC
07/H1008/168).Variant selection and genotyping
The UGT1A1 rs8175347 (TA)5–8 repeat variant of the TATA box motif and the
rs4124874 c.-3279T>G SNP of the phenobarbital enhancer module (PBREM) were
selected for testing because these two loci have good evidence of regulatory func-
tion and explain around 40–45% of the estimated variation in bilirubin levels in
healthy Europeans [19–23]. Although these two loci are in a fairly strong linkage
disequilibrium (r2 = 0.67) independent effects of the PBREM SNP over the (TA)n
repeat on serum bilirubin levels have been reported [19]. The UGT1A1 (TA)n
repeat was assayed using buccal samples (n = 2939) by a previously reported
size-separation technique using high-percentage polyacrylamide gels [24]. The
KASPar system by LGC Genomics, UK (http://www.lgcgenomics.com), was usedJournal of Hepatology 2014to type the PBREM SNP using blood samples (n = 2718). Call rates were >95%
for each variant. The reliability of the genotyping was checked by re-typing the
(TA)n repeat and the PBREM SNP in a random subset of duplicate samples.
Concordance was over 95% and there was also no evidence of deviation from
the Hardy–Weinberg equilibrium (p >0.05). All genotyping was done blind
without information on phenotypes.
Outcome deﬁnition
Forced expiratory volume in litres in one second (FEV1) and forced vital capacity
(FVC) in litres were measured during home visits at age 43 in 1989, at age 53 in
1999 and in clinical research facilities or at home visits between ages 60 and 64 at
the most recent follow-up during 2006–2011 using a Micro Medical turbine elec-
tronic spirometer (Cardinal Health UK 232 Ltd, Basingstoke, UK). Three measures
were recorded at age 43 and two at ages 53 and 60–64. Only participants where
at least two respiratory measures at each time point were taken and deemed sat-
isfactory by the nurse were included. The maximum readings at each of these
time points were used in the analysis. Of the 2939 participants with DNA, accept-
able respiratory function measures were available at age 43 for 2151, at age 53 for
2190 and at age 60–64 for 1531.
The presence of respiratory disease was deﬁned as either having chronic
obstructive pulmonary disease (COPD), asthma or a respiratory drug prescription
at any of the follow-up time points. Moderate to severe COPD was spirometrically
deﬁned as a predicted FEV1 below 80% and a FEV1/FVC ratio below 0.7 (i.e. Global
initiative for chronic obstructive lung disease stage 2 or higher). Predicted FEV1
was estimated using published algorithms derived from the British population
[25]. Presence of an asthma diagnosis was based on the participant reporting
recurring asthma at age 43 or clinically diagnosed asthma at age 53. Reports of
asthma were not collected at ages 60–64. Respiratory drug use was deﬁned as
a self-reported prescription of bronchodilators, corticosteroids, cromoglycate,
oxygen or mucolytics at ages 43, 53 or 60–64 years.
Statistical analyses
Mixed linear regression models, using a random subject effect to account for mul-
tiple measures in the same participants, were used to examine the relationship
between genotypes and mean respiratory function. The models included a ran-
dom intercept and random slope for age, specifying an unstructured covariance
matrix. We categorized the common genotypes as high expresser group 0 (homo-
zygous TA6), intermediate expresser group 1 (heterozygotes) and low expresser
group 2 (homozygous TA7) [22,23]. The rare (TA)5 allele was treated as (TA)6,
and (TA)8 as (TA)7 in the genotype categories [22,23]. Based on existing litera-
ture, the effect of this locus on bilirubin levels does not conform to the additive
genetic model with levels for group 1 only slightly higher than group 0 but
approximately double for group 2 vs. either group 0 or 1. Thus, we ﬁtted the locus
as a three level categorical variable and compared this with a simpler (recessive)
model with group 2 vs. groups 0/1. The UGT1A1 PBREM SNP (rs4124874) was cat-
egorized as high expressers (homozygous T), intermediate expressers (heterozy-
gotes) and low expressers (homozygous G), based on existing literature and the
SNP was included as a three level variable to test for any independent effect on
respiratory function over the (TA)n locus. Regression models initially included
important predictors of respiratory function, which were age (continuous), sex,
smoking status, height (continuous), and region of birth. Further details on how
these variables were measured are included in the Supplementary Patients and
methods. Although there is no prior evidence to suspect these variables would
differ by genotype they are important predictors of the respiratory outcome
and as such could improve the precision of estimation for other covariates in
the regression models [26]. Previous studies have reported that the importance
of genetic inﬂuences on respiratory function may become weaker with age [27]
and stronger in the presence of ROS exposure [28–30] and thus, in a pre-speciﬁed
analysis we tested for interactions between UGT1A1 variation, age and smoking
status. If any signiﬁcant interactions were identiﬁed, stratiﬁed analyses were per-
formed. Statistical signiﬁcance of categorical variables in regression models
including genotypes and interactions with genotypes were tested using the Wald
test. The PBREM SNP was added to the models already containing (TA)n geno-
types and the Wald test was used to test whether this locus exhibited an indepen-
dent effect over (TA)n.
A discrete-time proportional odds survival model was ﬁtted to estimate the
risk of respiratory disease across genotypes. The three time periods were included
as dummy variables in the model (birth to age 43, age 43 to 53, and age 53 to age
60–64) and a random subject effect was included to account for multiple obser-
vation periods in the same participants.
Mendelian randomization is a form of instrumental variable analysis for cau-
sal inference using observational data [14,31]. The phenotype of interest (i.e.vol. 61 j 1344–1351 1345
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Fig. 1. Flow diagram of cohort participants included in the analyses.
Research Articleserum bilirubin levels) is ‘instrumented’ using the genotype (i.e. UGT1A1 geno-
types) to identify and attempt to quantify the genetic component of the variation
and thus any causal relationships. Serum bilirubin measures were available for
ages 60–64 and these were used in a two-stage instrumental variable analysis
to further examine and quantify any causal relationships. Due to lower statistical
power and potential for bias from respiratory data missing at this collection point
(Supplementary Table 1), the results are included in the Supplementary data sec-
tion as a supportive analysis.
All analyses were carried out using Stata version 12.1. Probability values of
less than 5% (p <0.05) were considered statistically signiﬁcant assuming a two-
sided alternative hypothesis. A higher threshold of less than 10% (p <0.1) was
used for detecting potential interaction effects.Results
In total, complete genotype, respiratory function and covariate
data were available for 2190 participants at age 53 when the
DNA sample was taken (Fig. 1). The minor allele frequencies for
the (TA)n repeat variant (rs8175347) and the PBREM SNP
(rs4124874) loci were 0.30 (7 or 8 TA repeats) and 0.43 respec-
tively (Table 1). Consistent with existing literature, serum biliru-
bin levels measured in a subgroup of participants, remaining in
the cohort at ages 60–64, were highest in participants with the1346 Journal of Hepatology 2014UGT1A1 (TA)n genotype associated with Gilbert’s syndrome (Sup-
plementary Patients and methods and Table 1).
Mean FEV1 and FVC was higher for the (TA)n genotype asso-
ciated with Gilbert’s syndrome (group 2; [TA]7/7) with a sugges-
tion that the relationship was stronger in heavy smokers at older
ages (Table 2, Fig. 2). Never and ex-smokers at age 36 were
pooled because there were no signiﬁcant differences in respira-
tory function between these groups. There were no statistically
signiﬁcant univariable associations between UGT1A1 variation
and important predictors of respiratory function including sex,
height, smoking status and region of birth.
The (TA)n genotype underlying Gilbert’s syndrome (group 2;
[TA]7/7) was associated with signiﬁcantly higher FEV1 (p <0.001)
and FVC (p = 0.006) in the overall linearmixedmodel, including avail-
able respiratory data for all ages (Supplementary Table 2). There was
nostrong indicationthat respiratory functionwas lower intheUGT1A1
highexpresser category (group0)vs. the intermediatecategory (group
1) so we collapsed these into one group for further analyses. The
PBREM SNP was not independently related to respiratory function in
thismixed linearmodel after accounting for the (TA)nvariation. There
wasevidenceofagenetic interactionwithageandsmokingstatus, and
thus cross-sectional regression analyses were performed (Table 3).vol. 61 j 1344–1351
Table 1. Serum total bilirubin levels by UGT1A1 (TA)n repeat variant (rs8175347) and the PBREM SNP (rs4124874) measured between ages 60 and 64 in a cohort of
British adults.
UGT1A1 rs8175347 (TA)n (%) Genotype and allele 
frequencies
Number with bilirubin 
measures
Mean serum total bilirubin 
(± 1 SD)
(TA)5/6 - Group 0 7 (0) 4 (0) 7.0 (0.7)
(TA)6/6 - Group 0 1079 (49) 772 (50) 8.0 (3.2)
(TA)5/7 - Group 1 2 (0) 1 (0) 6.6 (0.0)
(TA)6/7 - Group 1 899 (41) 634 (41) 9.6 (4.1)
(TA)6/8 - Group 1 1 (0) 0
(TA)7/7 - Group 2 202 (9) 140 (9) 18.1 (7.9)
MAF [(TA)7 or (TA)8] 0.30
UGT1A1 rs4124874 c.-3279T>G (%)*
TT 711 (33) 518 (34) 7.9 (3.0)
TG 1043 (48) 725 (47) 9.2 (3.9)
GG 416 (19) 295 (19) 13.5 (7.5)
MAF 0.43
MAF, minor allele frequency; UGT1A1, uridine diphosphate-glucuronosyltransferase 1; SD, standard deviation.
⁄Numbers genotyped are lower for rs4124874 due to fewer blood samples collected vs. buccal samples used to genotype (TA)n.
Table 2. Characteristics of the adult members of the 1946 British birth cohort (MRC NSHD) with DNA samples, adequate respiratory function measures and smoking
data recorded at three follow-up periods (ages 43, 53, and 60–64).
Characteristic Overall
n = 2190
Group 0*
n = 1088
Group 1*
n = 900
Group 2*
n = 202
Male gender (%) 1092 (50) 556 (51) 437 (49) 99 (50)
Height, cm 169 (8.8) 169 (8.7) 169 (8.9) 169 (9.1)
FEV1
Age 43 (n = 2151) 3.02 L (0.70) 3.04 (0.7) 2.97 (0.71) 3.14 (0.69)
Age 53 (n = 2190) 2.81 L (0.70) 2.81 (0.69) 2.78 (0.69) 2.91 (0.69)
Age 60-64 (n = 1521) 2.60 L (0.71) 2.62 (0.71) 2.56 (0.72) 2.69 (0.65)
FVC
Age 43 (n = 2147) 3.67 L (0.90) 3.7 (0.89) 3.59 (0.89) 3.8 (0.93)
Age 53 (n = 2190) 3.51 L (0.90) 3.52 (0.89) 3.47 (0.91) 3.6 (0.88)
Age 60-64 (n = 1531) 3.29 L (0.90) 3.31 (0.9) 3.25 (0.9) 3.37 (0.88)
Smoking status at age 53 (%) 
Never/ex by age 36 1405 (64) 694 (64) 577 (64) 134 (66)
Light to moderate 558 (26) 291 (27) 222 (25) 45 (22)
Heavy 227 (10) 103 (9) 101 (11) 23 (11)
Total numbers with percentages (in parentheses) are reported for categorical variables and means with ± 1 standard deviation (in parentheses) for continuous variables
(height measured in cm and FEV1 and FVC in litres).
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
⁄Group 0 = (TA)5/6 or (TA)6/6; Group 1 = (TA)5/7, (TA)6/7, (TA)6/8; Group 2 = (TA)7/7 (underlying Gilbert’s syndrome).
JOURNAL OF HEPATOLOGYOverall, the results suggest that the genetic effects on respira-
tory function become weaker in never/ex-smokers as cohort
members age, whereas for heavy smokers the genetic effect
seemed to be stronger at older ages. At age 43, the differences
in respiratory function between (TA)n groups were fairly similar
across smoking categories although there was a suggestion that
the magnitude of the difference was greater for heavy smokers
(Table 3). At age 53 mean FEV1 was 409 ml higher (p <0.001) in
heavy smokers and FVC was 530 ml higher (p <0.001) for those
with the genotype underlying Gilbert’s syndrome (group 2;
[TA]7/7) compared to those without this genotype, whereas the dif-
ferences for other smoking categories at this age were weaker and
non-signiﬁcant (Table 3). The genetic associations at age 60–64
were also stronger for heavy smokers compared with age 43 but
statistical power was lower due to a smaller sample size (Table 3).Journal of Hepatology 2014Examination of the possible independent association of the
PBREM SNP (rs4124874) with respiratory function, after adjust-
ment for the effect of (TA)n showed evidence of some residual
effect in heavy smokers at age 53 (p = 0.05 for FEV1 and
p = 0.02 for FVC). Mean FEV1 in heterozygotes was 203 ml higher
(95%; 0 to 407 ml) and mean FVC was 173 ml higher (95%; 1 to
426 ml) compared with homozygotes for the high expresser
allele (data not shown). Including both loci in the regression
models for heavy smokers at age 53, increased the explainable
variability (R2) in respiratory function by 9% for FEV1 and 8%
for FVC. For comparison, the amount of variability explained by
differences in height for this group was 13% for FEV1 and 16%
for FVC.
The genotype underling Gilbert’s syndrome (group 2; [TA]7/7)
was associated with 50% lower odds of overall respiratory diseasevol. 61 j 1344–1351 1347
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Fig. 2. Mean FEV1 and FVC expressed in litres, with 95% CI by age and
smoking status in a cohort of British adults followed since birth. Group
0 = (TA)5/6 or (TA)6/6; Group 1 = (TA)5/7, (TA)6/7, (TA)6/8; Group 2 = (TA)7/7
(underlying Gilbert’s syndrome). (This ﬁgure appears in colour on the web.)
Research Article(Table 4). The effect sizes were similar across COPD, asthma and
respiratory drug prescriptions (Table 4). Interactions with smok-
ing status were suggested but were not statistically signiﬁcant
possibly due to lower power for this binary outcome relative to
continuous respiratory function.
The instrumental variable analysis including respiratory mea-
surements at all ages and serum bilirubin measures estimated
that a 10% increase in serum bilirubin levels was associated with
an average 13 ml increase in both FEV (95% CI 4–22 ml; p = 0.007)
and FVC (95% CI 2–24 ml; p = 0.02) (Supplementary Tables 3 and
4). The relationships were strongest in heavy smokers at age 53
with a 10% increase in serum bilirubin level associated with an
average 77 ml increase in FEV (95% CI 35–119 ml; p <0.001) and
a 79 ml increase in FVC (95% CI 28–130 ml; p = 0.002) (Supple-
mentary Tables 3 and 4).
Excluding the small number of participants with rare (TA)5 or
(TA)8 alleles had no impact on any of the relationships examined.Discussion
In the present study, we have shown that participants in the 1946
British birth cohort predisposed to Gilbert’s syndrome due to low
expression of the enzyme UGT1A1 have higher respiratory func-
tion and lower rates of respiratory disease relative to those with-
out this predisposition. The genetic relationships seemed to be
strongest amongst heavy smokers after age 43. The similar mag-
nitude of the effect on FEV1 and FVC suggests that UGT1A1 and
unconjugated bilirubin may have a protective role for both
obstructive and restrictive respiratory diseases. These results
lend support to a causal relationship between raised serum
unconjugated bilirubin and protection of the respiratory system
against the harmful effects of heavy smoking and show the ben-
eﬁcial effect of Gilbert’s syndrome in this context. This protective
effect may extend to other environmental sources of oxidants as1348 Journal of Hepatology 2014well as cigarette smoke such as air pollution and to protection
from certain types of lung cancer.
To the best of our knowledge, the present study is the ﬁrst to
examine respiratory function and disease in people with the cau-
sal variant underlying Gilbert’s syndrome and to show an interac-
tion with smoking status. Another group recently reported
associations between a SNP, linked to bilirubin levels from gen-
ome wide association studies and respiratory function in a Swiss
cohort [9]. This study reported interactions with serum bilirubin
and smoking status for the full cohort (n = 4195) but lacked
power to examine genetic interactions with smoking for the sub-
set with DNA (n = 982). Overall, the genetic effects appear slightly
weaker than for our study although differences in age, smoking
behaviour and the exclusion of patients with a history of asthma
may explain these differences. Genetically reduced haem oxygen-
ase 1 activity, resulting in lower bilirubin levels, has also been
associated with poorer respiratory function and a higher risk of
respiratory disease with the effect strongest in heavy smokers
(P20 cigarettes per day) [32,33]. However, pleiotropy is a possi-
bility for those studies of haem oxygenase 1 where polymor-
phisms also lower the production of other products of the
pathway that may inﬂuence respiratory function including car-
bon monoxide. Genetic variation of UGT1A1 has been associated
with other diseases where oxidative stress is purported to play
a pathophysiological role. For example, longitudinal studies with
long-term follow-up, including the Framingham Offspring cohort
study, have reported 50–80% lower rates of cardiovascular dis-
ease and mortality in people with UGT1A1 (TA)n genotype associ-
ated with Gilbert’s syndrome or linked loci [34–36]. However,
these relationships are not consistently replicated [37].
The strengths of the current study include the long-term
follow-up, allowing analysis of respiratory function over a
20-year period, standardized measurement of phenotypes and
the use of a strong genetic instrument for bilirubin levels. Limita-
tions include self-reported smoking status, asthma and drug use,
and the spirometric deﬁnition of COPD without knowledge of
symptoms. There may also be some sources of bias. For example,
the genetic associations could have been diluted if participants
with genetically lower bilirubin levels were more likely to drop
out of the cohort before age 53 due to poor health or death before
the DNA sample was taken. In the instrumental variable analysis,
the stronger causal estimates using genetic instruments vs.
regression coefﬁcients from using serum bilirubin may suggest
that the relationship between serum bilirubin measures and
respiratory health are underestimated, due to factors such as
regression dilution bias, model misspeciﬁcation (assuming a lin-
ear relationship), reverse causation and negative confounding
from drugs and disease processes. Certain antioxidant systems,
including haem oxygenase 1 (the ﬁrst step in bilirubin produc-
tion), are upregulated in response to disease processes, suggest-
ing that reverse causation is a possibility. Stronger causal
estimates from genetic instrumental variable analyses vs. other
study designs have also been reported with respect to low-den-
sity lipoprotein cholesterol and the risk of coronary heart disease
[38]. The results of the study are broadly generalizable to the
British post-war generation who were mainly of UK/northern
European ancestry [17] but the relationships in non-European
ethnic groups require further study. Finally, we have used an
instrumental variable approach to support causality but this
relies on some important assumptions, including absence of con-
founding by pleiotropy (genes affecting multiple traits), linkagevol. 61 j 1344–1351
Table 3. Association between UGT1A1 rs8175347 (TA)n repeat variants and measures of respiratory function at each age stratiﬁed by smoking status in a cohort of
British adults.
FEV1 (ml) FVC (ml)
β coefficients (95%CI)† β coefficients (95%CI)†
Variable and regression model Number UGT1A1 (TA)n group 2 vs. 0/1* p value Number UGT1A1 (TA)n group 2 vs. 0/1* p value
Age 43
Overall 2151 122 (49 to 194) 0.001 2147 133 (39 to 227) 0.005
Never/ex-smokers 1379 128 (38 to 217) 0.005 1376 159 (45 to 274) 0.006
Light-moderate 462 71 (-92 to 235) 0.392 461 -22 (-233 to 190) 0.841
Heavy 310 205 (14 to 396) 0.035 310 296 (30 to 562) 0.029
Age 53
Overall 2190 105 (38 to 172) 0.002 2190 92 (8 to 175) 0.032
Never/ex-smokers 1405 79 (-3 to 161) 0.058 1405 68 (-34 to 170) 0.193
Light-moderate 558 63 (-79 to 204) 0.386 558 -35 (-213 to 142) 0.695
Heavy 227 409 (191 to 627) <0.001 227 530 (262 to 798) <0.001
Age 60-64 
Overall 1521 98 (10 to 185) 0.029 1531 81 (-26 to 188) 0.138
Never/ex-smokers 1036 87 (-14 to 189) 0.092 1043 86 (-42 to 215) 0.187
Light-moderate 416 111 (-77 to 300) 0.247 417 49 (-162 to 260) 0.649
Heavy 69 538 (46 to 1029) 0.033 71 356 (-339 to 1052) 0.309
FEV1 and FVC are expressed as change in volume measured in ml.
⁄Group 0 = (TA)5/6 or (TA)6/6; Group 1 = (TA)5/7, (TA)6/7, (TA)6/8; Group 2 = (TA)7/7 (underlying Gilbert’s syndrome).
Regression coefﬁcients for models including sex, height, and birth region.
Table 4. Association between UGT1A1 rs8175347 (TA)n repeat variants and respiratory disease up to age 60–64 (COPD, asthma, or respiratory drug use) in a cohort of
British adults followed since birth in 1946.
Number of cases (% of cohort) Adjusted odds ratio (95% CI)†
(TA)n group 2 vs. 0/1
p value
Respiratory disease 478 (21.8) 0.49 (0.32 to 0.74) <0.001
292 (13.3) 0.49 (0.29 to 0.84) 0.009
Asthma by age 53 211 (9.6) 0.34 (0.17 to 0.70) 0.003
Respiratory drugs 181 (8.3) 0.53 (0.27 to 1.04) 0.064
⁄Group 0 = (TA)5/6 or (TA)6/6; Group 1 = (TA)5/7, (TA)6/7, (TA)6/8; Group 2 = (TA)7/7 (underlying Gilbert’s syndrome).
Discrete-time proportional odds survival model controlling for sex, height, smoking status, and birth region.
JOURNAL OF HEPATOLOGYdisequilibrium (where due to co-inheritance the variant under
study may be a proxy for the causal variant or confounded by a
linked variant), and population stratiﬁcation (spurious associa-
tions due to ancestry differences, for example associated with
geographic differences in genotype frequencies across study
groups) [14]. The 1946 Birth cohort is predominantly white
European and we adjusted for possible geographic effects to
reduce any potential genetic stratiﬁcation. The UGT1A1 gene is
located in a gene complex that encodes several other UGT1A
isoforms involved in glucuronidation of many other endogenous
and exogenous molecules. A region of linkage disequilibrium
exists across the complex and encompasses other variants with
purported function [39]. Thus, it is plausible that the relation-
ships in the present study reﬂect substrate effects of a different
UGT1A isoform although there are no biologically plausible
candidates that we are aware of at present. A further complexity
is that antioxidants can increase UGT1A1 expression as the result
of interactions of a signalling pathway, involving the transcrip-
tion factor Nrf2 via regulatory elements, which overlap with
the PBREM region [40].
The amount of variability in respiratory function explained
by the UGT1A1 variation in heavy smokers suggests a role inJournal of Hepatology 2014predicting adult respiratory outcomes and further research is
required to investigate this empirically in larger independent
cohorts. The results of the present study support but do not prove
causality. Randomised controlled studies of the short-term effect
of bilirubin infusions or drugs that speciﬁcally inhibit UGT1A1
activity on respiratory and endothelial function in humans are
perhaps possible, with similar studies carried-out for another
serum antioxidant, uric acid, suggesting a physiological beneﬁt
[41].
The high frequency of various alleles causing mild hyperbi-
lirubinaemia and Gilbert’s syndrome across human populations,
including a relatively common non-synonymous SNP of UGT1A1
in East Asian groups, has led to the speculation that there has
been a balancing selection. One theory is that neurotoxicity,
induced by very high bilirubin levels in neonates, prevents the
alleles causing hyperbilirubinaemia from being more common
across populations [42,43]. It should be noted, however, that in
certain regions of Equatorial Africa, UGT1A1 promoter alleles that
cause Gilbert’s syndrome in Europeans are more common than
those associated with normal bilirubin levels [43]. Protection
from cigarette and other smoke in the environment of adult
modern humans may not have had much impact on reproductivevol. 61 j 1344–1351 1349
Research Article
outcome. Although laboratory research has focused on antioxi-
dant properties of raised bilirubin, protection against respiratory
infections, such as pneumonia and bronchitis is also a plausible
explanation for the results of the present study [44], and arguably
a more compelling hypothesis for the high frequency of alleles
causing mild hyperbilirubinaemia rather than protection against
chronic late-onset diseases. The potential role of the UGT1A1 var-
iation and bilirubin levels in the susceptibility to respiratory
infections across the life course is an interesting topic for further
research.
In summary, a common genetic variation of the UGT1A1 gene,
causing moderately raised bilirubin and Gilbert’s syndrome, is
associated with signiﬁcantly higher respiratory function in adults
with the strongest effects seen in heavy smokers, and lower rates
of respiratory disease. This may reﬂect antioxidant or other pro-
tective properties of serum bilirubin.Financial support
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